Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sammy Chebon

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
American Journal of Hematology|June 17, 2024
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitionAlexander Röth, Guangsheng He, Hongyan Tong, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Lancet. Haematology|April 21, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studySteven W Pipe, Midori Shima, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
American Journal of Hematology|June 17, 2024
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitionAlexander Röth, Guangsheng He, Hongyan Tong, et al.
Pageof 2